Lawrence Ganti is a seasoned executive with over 25 years of experience leading companies through transformations, transitions, and scale-ups. He currently serves as the CEO of Fortify, a defense tech startup focused on next generation antenna devices. He recently closed a Series B round of funding which included the first ever co-investment from Lockheed Martin and Raytheon.
Prior to Fortify, Lawrence served as the President of SiO2 Materials Science, where he led the scale-up of the company during Covid-19. While pivoting the company, he secured over $200m in non-dilutive investment from the US Government and subsequently served on the Presidential task force “Operation Warp Speed” as a key operator for the pandemic response. At SiO2, he oversaw a 400% growth in manufacturing capacity and grew sales from $1m to $50m annually.
Lawrence has a demonstrated track record of helping founders and venture capitalists scale their companies. Through mentorship, fundraising, and direct operating, he has raised over $1 billion of capital, launched million-dollar products, created award winning marketing campaigns, structured public private partnerships, and grew companies with award winning record results. Lawrence spent his formative years climbing the corporate ladder at pharma and chemicals giant, Merck. During his 16 year career with Merck, he lived and managed businesses in the US, Europe, Japan, China, India, Middle East, and Latin America. As the CEO of Latin America, he led a team of 3,000 employees driving $1.5 billion in revenues. His exceptional leadership has earned him numerous CEO Awards for Leadership, Business Performance, Talent Development, and Change Management.
Lawrence is an active angel investor. He currently supports founders in the Fashion, AI Software, Deep Tech, AgriBio, Digital Health, and Medical Device sectors. Lawrence serves on the boards of numerous startups; is on the Oversight Committee of Canopy Healthtech and maintains mentoring relationships with former employees and many start-up founders. He is a published author on the topics of Transitioning from R&D to Commercialization and frequently writes for Forbes and FastCompany.
Lawrence started his career in Pharmaceutical Sales for Johnson & Johnson and then did ethnographic research for a joint initiative between McKinsey & Company and Harvard Business School.
Lawrence obtained his BA from Babson College, where he served as Class President and Editor in Chief of the Babson Free Press. He obtained his MBA from the International Institute for Management Development (IMD) in Lausanne, Switzerland. He is an alumni of various executive education programs at Wharton and Kellogg.